stockrowBolt Biotherapeutics, Inc.
BOLT Healthcare Biotechnology
Bolt Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, roughly unchanged from fiscal 2024.
- Revenue
- −99.7%
- EPS
- −2.47%
- Free cash flow
- +38.9%
- Total debt
- −14.3%
Quarter to June 2026, against a year earlier
Follow BOLT
Alert me
Bolt Biotherapeutics, Inc. (BOLT) EV/Sales
As of 6 November 2026, Bolt Biotherapeutics, Inc. (BOLT) trades at a EV/Sales of 2.5×. Over the past ten years it has ranged from −54.8× (May 2022) to 314× (October 2021); the current reading is higher than 96% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.3× | — |
| FY2024 | −0.6× | — |
| FY2023 | −5.2× | — |
| FY2022 | −17.0× | — |
| FY2021 | −1.1× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 228.77% |
| Mar 2026 | 0.5× | 35.87% |
| Dec 2025 | 0.3× | — |
| Sep 2025 | −0.3× | — |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GUTS Fractyl Health, Inc. compare | −51.6× |
| LPCN Lipocine Inc. compare | −1.6× |
| AEON AEON Biopharma, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | n/m |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | 1.8× |
| BOLT Bolt Biotherapeutics, Inc. | 2.5× |
| DARE Dare Bioscience, Inc. compare | 3.6× |
| HIND Vyome Holdings, Inc. compare | 125× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)